TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12631165

Group type: EXPERIMENTAL
Intervention: Appliance protecting the lesion from abrasion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: No appliance (unprotected)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (unexposed)
Number of subjects: 10
Study: 11071188

Group type: EXPERIMENTAL
Intervention: Sodium cromoglicate by inhalation
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Sodium cromoglicate by nasal route
Number of subjects: 2
Study: 8725678

Group type: EXPERIMENTAL
Intervention: Two-dimensional and contrast echocardiography
Number of subjects: 20
Study: 1533372

Group type: EXPERIMENTAL
Intervention: Balloon Angioplasty (BA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Atherectomy (AT)
Number of subjects: 30
Study: 3513682

Group type: EXPERIMENTAL
Intervention: Vaccinia Melanoma Oncolysates (VMO)
Number of subjects: 48
Study: 31329520

Group type: EXPERIMENTAL
Intervention: Identification of a proximal vessel occlusion
Number of subjects: 12048

Group type: EXPERIMENTAL
Intervention: Patient's age
Number of subjects: 12048

Group type: EXPERIMENTAL
Intervention: Time elapsed from symptom onset to consultation
Number of subjects: 12048
Study: 28646587

Group type: EXPERIMENTAL
Intervention: Mini-catheter for local anesthetic injection (chirochaine 0.125% w/v; 20 mL bolus before consciousness, followed by three consecutive injections of 20 mL each at 8, 16, and 24 hours post-surgery)
Number of subjects: 31
Study: 26861582

Group type: EXPERIMENTAL
Intervention: 3D-printed models (Group B, n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 3D-computer models (Group A, n = 15)
Number of subjects: 30
Study: 24953576

Group type: EXPERIMENTAL
Intervention: Glycerin suppository (1g) once a day from day‐2 to day‐14 of life
Number of subjects: 50

Group type: COMPARATOR
Intervention: No suppository
Number of subjects: 50
Study: 21546099

Group type: EXPERIMENTAL
Intervention: Daily vardenafil 10mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: On-demand vardenafil 20mg
Number of subjects: 20
Study: 20159252

Group type: EXPERIMENTAL
Intervention: Infant-onset eczema
Number of subjects: 2916

Group type: EXPERIMENTAL
Intervention: Eczema limited to infancy
Number of subjects: 2916

Group type: EXPERIMENTAL
Intervention: Eczema persistence
Number of subjects: 2916
Study: 18308653

Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg weekly)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 15991553

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy with Novo‐Helisen Depot allergy vaccines for 3 years
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 36
Study: 12912694

Group type: EXPERIMENTAL
Intervention: Elective treatment (enucleation or eye-conserving radiotherapy)
Number of subjects: 8712

Group type: EXPERIMENTAL
Intervention: Tumor size greater than 15.0 mm
Number of subjects: 8712

Group type: EXPERIMENTAL
Intervention: Juxtapapillary tumors
Number of subjects: 8712
Study: 10350559

Group type: EXPERIMENTAL
Intervention: Single visual stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paired visual stimulation
Number of subjects: 0
Study: 8821108

Group type: EXPERIMENTAL
Intervention: 1% triclosan-based handwash
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 1% triclosan with 5% PI
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate (CHG)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 7.5% povidone-iodine (PI)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Nonantimicrobial liquid soap
Number of subjects: 5
Study: 1951474

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nicardipine
Number of subjects: 16
Study: 6119096

Group type: EXPERIMENTAL
Intervention: bunitrolol (10 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 31145833

Group type: EXPERIMENTAL
Intervention: Patient-caregiver dyads who agreed on a poor prognosis
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Patient-caregiver dyads who disagreed regarding prognosis
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Patient-caregiver dyads who both believed the patient's future quality of life would be good (34%) and that the patient would live for ≥2 years (30%)
Number of subjects: 141
Study: 27118716

Group type: EXPERIMENTAL
Intervention: Systemic cognitive training
Number of subjects: 73

Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 73
Study: 26509682

Group type: EXPERIMENTAL
Intervention: Muscle-Energy Techniques (MET) - 2 treatment sessions per week for 6 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group - no intervention during the 6-week period
Number of subjects: 39
Study: 23683378

Group type: EXPERIMENTAL
Intervention: In-plane with GPS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Out-of-plane with GPS
Number of subjects: 30

Group type: COMPARATOR
Intervention: In-plane no GPS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Out-of-plane no GPS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GPS technique
Number of subjects: 30
Study: 21621716

Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab
Number of subjects: 636

Group type: COMPARATOR
Intervention: Erlotinib plus placebo (control)
Number of subjects: 636
Study: 19647382

Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.45 mg
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.625 mg
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: BZA/CE
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 17183623

Group type: EXPERIMENTAL
Intervention: Combination of disease modifying antirheumatic drugs (DMARD; COMBI)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Single DMARD (SINGLE)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Sustained DAS28 remission
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Lost DAS28 remission after 6 months
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Not in remission at 6 months
Number of subjects: 169
Study: 15215224

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin (1000/500 mg) instilled
Number of subjects: 18

Group type: COMPARATOR
Intervention: Imipenem/cilastatin nebulized
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tobramycin (200 mg) instilled
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tobramycin nebulized
Number of subjects: 18
Study: 12577413

Group type: EXPERIMENTAL
Intervention: SHSBG and CT (treated group 1)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: SHSBG after CT (treated group 2)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Rubidate and CT (control group 1)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Rubidate after CT (control group 2)
Number of subjects: 112
Study: 9848044

Group type: EXPERIMENTAL
Intervention: Acellular allogenic dermis and a thin autograft
Number of subjects: 6

Group type: COMPARATOR
Intervention: Autograft alone (control)
Number of subjects: 6
Study: 8033956

Group type: EXPERIMENTAL
Intervention: Benserazide (inhibition of DOPA decarboxylase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (without benserazide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benserazide
Number of subjects: 0
Study: 2685179

Group type: EXPERIMENTAL
Intervention: d14 BM M1 (less than 5% blasts)
Number of subjects: 2516

Group type: EXPERIMENTAL
Intervention: d14 BM M2 (4% to 25% blasts)
Number of subjects: 2516

Group type: EXPERIMENTAL
Intervention: d14 BM M3 (greater than 25% blasts)
Number of subjects: 2516

Group type: EXPERIMENTAL
Intervention: d14 BM M1 after late randomization
Number of subjects: 2516

Group type: EXPERIMENTAL
Intervention: d14 BM M2 after late randomization
Number of subjects: 2516

Group type: EXPERIMENTAL
Intervention: d14 BM M3 after late randomization
Number of subjects: 2516
Study: 557329

Group type: EXPERIMENTAL
Intervention: Inhalation provocation tests with formalin
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Exposure to formalin
Number of subjects: 28
Study: 31582598

Group type: EXPERIMENTAL
Intervention: irradiation+fluoride
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: irradiation+CPP‐ACP
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: irradiation+CPP‐ACP+fluoride
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: irradiation+infiltration resin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: irradiation+infiltration resin+fluoride
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: irradiation+infiltration resin+CPP‐ACP
Number of subjects: 120

Group type: COMPARATOR
Intervention: blank control
Number of subjects: 120

Group type: COMPARATOR
Intervention: irradiation control
Number of subjects: 120
Study: 30851499

Group type: EXPERIMENTAL
Intervention: Ultrasound guided erector spinae plane (ESP) block with 0.5 ml/kg 0.25% bupivacaine (max 20 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultrasound guided Quadratus Lumborum Block (QLB) with 0.5 ml/kg 0.25% bupivacaine (max 20 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ESP block
Number of subjects: 60

Group type: COMPARATOR
Intervention: QLB block
Number of subjects: 60
Study: 29138131

Group type: EXPERIMENTAL
Intervention: CHESS+CR (Clinician Report)
Number of subjects: 235

Group type: COMPARATOR
Intervention: CHESS-Only
Number of subjects: 235
Study: 26506582

Group type: EXPERIMENTAL
Intervention: Guanfacine Extended Release (GXR) 1-7 mg per day
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Guanfacine Extended Release (GXR)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 22974284

Group type: EXPERIMENTAL
Intervention: Optimized formulation (CCT T8) with core tablet (C8) and mannitol, lag time of 6 hrs before immediate release of drug.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimized solid dispersion (S9) used for formulating optimized core tablet formulation (C8).
Number of subjects: 0
Study: 21300933

Group type: EXPERIMENTAL
Intervention: Cetuximab plus CAPIRI (irinotecan 200 mg/m(2), capecitabine 800 mg/m(2) twice daily)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Cetuximab plus CAPOX (oxaliplatin 130 mg/m(2), capecitabine 1,000 mg/m(2) twice daily)
Number of subjects: 185
Study: 19904601

Group type: EXPERIMENTAL
Intervention: GIII series (Vitrolife)
Number of subjects: 512

Group type: COMPARATOR
Intervention: ISM (Medicult)
Number of subjects: 512
Study: 16989024

Group type: EXPERIMENTAL
Intervention: Imiquimod cream applied 5 or 7 days a week for six weeks
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Imiquimod cream applied 5 times a week
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Imiquimod cream applied daily
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Non-comparative trial with imiquimod
Number of subjects: 724

Group type: COMPARATOR
Intervention: Surgical excision (standard treatment)
Number of subjects: 724
Study: 12628884

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (MA) 160 mg (8 mL)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (saline solution 8 mL)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (MA)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 67
Study: 10977039

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (100 IU/orally for 3 months)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 29
Study: 9091333

Group type: EXPERIMENTAL
Intervention: Fimbrioplasty and salpingostomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salpingostomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bilateral salpingostomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fimbrioplasty
Number of subjects: 0
Study: 8165613

Group type: EXPERIMENTAL
Intervention: Textarin/Ecarin test system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Textarin with polybrene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Factor V deficiency and specific inhibitors of factor V
Number of subjects: 0
Study: 3752464

Group type: EXPERIMENTAL
Intervention: Controlled ventilation without glycopyrronium
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Spontaneously breathing without glycopyrronium
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Controlled ventilation with glycopyrronium (7.5 micrograms/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Spontaneously breathing with glycopyrronium (7.5 micrograms/kg)
Number of subjects: 100
Study: 31043093

Group type: EXPERIMENTAL
Intervention: Wellness-education intervention over 8 weeks
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (no wellness-education intervention)
Number of subjects: 138
Study: 30518774

Group type: EXPERIMENTAL
Intervention: Japanese version of the Edinburgh Postnatal Depression Scale (EPDS)
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Confirmatory factor analysis of the EPDS
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: EPDS
Number of subjects: 1075
Study: 26649879

Group type: EXPERIMENTAL
Intervention: mHealth intervention (mobile phone app plus Fitbit)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Fitbit)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 30
Study: 24656153

Group type: EXPERIMENTAL
Intervention: 10‐mg generic formulation (test)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Branded formulation (reference)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study: 22176850

Group type: EXPERIMENTAL
Intervention: Reminder group (n=1374)
Number of subjects: 3618

Group type: COMPARATOR
Intervention: No reminder group
Number of subjects: 3618

Group type: EXPERIMENTAL
Intervention: Undeliverable reminder group
Number of subjects: 3618
Study: 20391081

Group type: EXPERIMENTAL
Intervention: 6.4% carbohydrate-electrolyte solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo solution (8 ml x kg BM(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 10
Study: 17922561

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.2mg/70kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.4mg/70kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone (continuous infusion)
Number of subjects: 0
Study: 15988430

Group type: EXPERIMENTAL
Intervention: Brief intervention conducted by peer educators (20-minute semiscripted interview)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 295
Study: 12706638

Group type: EXPERIMENTAL
Intervention: Reviparin-sodium (low molecular weight heparin), administered twice daily.
Number of subjects: 158

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 158
Study: 10637141

Group type: EXPERIMENTAL
Intervention: Duplex ultrasound scanning
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Clinical surveillance
Number of subjects: 1200
Study: 9122553

Group type: EXPERIMENTAL
Intervention: Bedsharing
Number of subjects: 12

Group type: COMPARATOR
Intervention: Solitary-sleeping
Number of subjects: 12
Study: 1912675

Group type: EXPERIMENTAL
Intervention: First chemotherapy (105 women)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Breast conservation therapy (64 women)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Self-evaluation by 64 women one year after treatment
Number of subjects: 206

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (78 women)
Number of subjects: 206
Study: 6874413

Group type: EXPERIMENTAL
Intervention: Safflower seed oil (60 ml/d)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Aspirin (900 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Basal diet
Number of subjects: 6
Study: 30831478

Group type: EXPERIMENTAL
Intervention: Personalized modular treatment based on cognitive-behavioral therapy
Number of subjects: 32
Study: 27780895

Group type: EXPERIMENTAL
Intervention: Personalized lung cancer risk projections calculated using the LLP risk model
Number of subjects: 513
Study: 27523719

Group type: EXPERIMENTAL
Intervention: Albuterol MDPI 180 μg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Albuterol HFA 180 μg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Albuterol MDPI and HFA
Number of subjects: 15
Study: 24158227

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 839

Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: Nicotine patch (8-week treatment)
Number of subjects: 839
Study: 22999073

Group type: EXPERIMENTAL
Intervention: Abciximab treatment in group A (additional platelet inhibition)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional anticoagulation with heparin in group C1 (control group)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional anticoagulation with heparin in group C2 (control group)
Number of subjects: 130
Study: 20393175

Group type: EXPERIMENTAL
Intervention: Combination therapy (infliximab + azathioprine)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Infliximab monotherapy
Number of subjects: 508

Group type: COMPARATOR
Intervention: Azathioprine monotherapy
Number of subjects: 508
Study: 17678774

Group type: EXPERIMENTAL
Intervention: Topographic method (calculated depth based on landmarks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 15-cm fixed length
Number of subjects: 100
Study: 16282139

Group type: EXPERIMENTAL
Intervention: Rawls' theory of justice
Number of subjects: 0
Study: 12351526

Group type: EXPERIMENTAL
Intervention: Continuation of GnRH agonist administration for 1 week after hCG injection
Number of subjects: 138

Group type: COMPARATOR
Intervention: Elective cryopreservation of all pronucleate embryos
Number of subjects: 138
Study: 10540091

Group type: EXPERIMENTAL
Intervention: Remifentanil 3 microg x kg‐1 (group R3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil 4 microg x kg‐1 (group R4)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil 5 microg x kg‐1 (group R5)
Number of subjects: 60
Study: 7776303

Group type: EXPERIMENTAL
Intervention: Palpable uterine artery pulsation
Number of subjects: 299

Group type: COMPARATOR
Intervention: No palpable uterine artery pulsation
Number of subjects: 299
Study: 2153780

Group type: EXPERIMENTAL
Intervention: Algorithmic‐based instruction (ABI)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Teacher‐directed instruction (TDI)
Number of subjects: 55
Study: 7423170

Group type: EXPERIMENTAL
Intervention: Oral zinc sulfate (220 mg, three daily doses)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 31958000

Group type: EXPERIMENTAL
Intervention: Swimming program for 10 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: No exercise program (control group)
Number of subjects: 40
Study: 30448193

Group type: EXPERIMENTAL
Intervention: Supplemental parenteral nutrition (SPN)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (continued enteral nutrition)
Number of subjects: 23
Study: 28873109

Group type: EXPERIMENTAL
Intervention: Clindamycin cream 0.3% once daily
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Clindamycin cream 1% once or twice daily
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Clindamycin gel 1% twice daily
Number of subjects: 629

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 629
Study: 27313086

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine group (six courses of alternating R-CHOP or R-DHAP followed by high-dose cytarabine-containing conditioning regimen and ASCT)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Control group (six courses of R-CHOP followed by myeloablative radiochemotherapy and ASCT)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine group
Number of subjects: 497

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 497
Study: 25019551

Group type: EXPERIMENTAL
Intervention: Mindfulness practice quality
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mindfulness practice time
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mindfulness practice quality and time
Number of subjects: 43
Study: 22546988

Group type: EXPERIMENTAL
Intervention: abacavir/lamivudine (ABC/3TC)
Number of subjects: 244

Group type: COMPARATOR
Intervention: tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: efavirenz (EFV)
Number of subjects: 244

Group type: COMPARATOR
Intervention: atazanavir/ritonavir (ATV/r)
Number of subjects: 244
Study: 19616668

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg/day, up titrated to 40 mg/day
Number of subjects: 102

Group type: COMPARATOR
Intervention: Amlodipine 5 mg/day, up titrated to 10 mg/day
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 102

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 102
Study: 17135223

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0
Study: 14759940

Group type: EXPERIMENTAL
Intervention: Multicultural smoking prevention curriculum
Number of subjects: 1430

Group type: COMPARATOR
Intervention: Standard curriculum
Number of subjects: 1430
Study: 11401925

Group type: EXPERIMENTAL
Intervention: Folate supplementation (5 mg daily for 1 year)
Number of subjects: 20
Study: 9479360

Group type: EXPERIMENTAL
Intervention: Adjuvant immunotherapy with tularemia booster (TB) and anticoagulant treatment (fibrinolysin, pelentan, and aspirin)
Number of subjects: 97

Group type: COMPARATOR
Intervention: No vaccination (control group 1)
Number of subjects: 97

Group type: COMPARATOR
Intervention: TB inoculation without anticoagulants (control group 2)
Number of subjects: 97
Study: 8200552

Group type: EXPERIMENTAL
Intervention: Misoprostol (n = 5)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 15